mRNA 治疗市场规模、份额和成长分析（按类型、应用、最终用户和地区）- 产业预测 2025-2032

mRNA 治疗市场规模预计在 2023 年达到 110 亿美元，并从 2024 年的 117.1 亿美元增长到 2032 年的 193.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.5%。

mRNA 治疗市场经历了显着成长，尤其是在慢性病治疗领域，这主要归功于 Moderna 和 Pfizer-BioNTech 在 COVID-19 大流行期间成功推出的 mRNA 疫苗。由于这些疫苗在生产和分发过程中的安全性和效率，它们比 DNA 疫苗越来越受到青睐。人体临床试验的成功增加了需求，特别是在肿瘤学领域，癌症 mRNA 疫苗的临床试验引起了志愿者的极大兴趣。随着新的 SARS-CoV-2 变体的出现，对有效的 mRNA 解决方案的需求变得更加迫切。技术进步正在提高 mRNA 产品的稳定性和递送，显示该领域具有改变个人化医疗、重塑医疗保健标准和刺激市场扩张的潜力。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 宏观经济指标
• 价值链分析
• 定价分析
• 监管分析
• 专利分析

mRNA 治疗市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• 预防
• 治疗

mRNA 治疗药物市场规模（依应用划分）及复合年增长率（2025-2032）

• 市场概况
• 感染疾病
• 瘤
• 罕见遗传疾病
• 呼吸系统疾病
• 其他的

mRNA 治疗药物市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院和诊所
• 研究组织
• 其他的

mRNA 治疗市场规模（按地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Lonza Group（Switzerland）
• Samsung Biologics（South Korea）
• Fujifilm Diosynth Biotechnologies（Japan）
• Catalent（United States）
• BioNTech（Germany）
• Ionis Pharmaceuticals（United States）
• WuXi Biologics（China）
• CordenPharma（Germany）
• WuXi AppTec（China）
• Boehringer Ingelheim（Germany）
• Samsung Biologics（South Korea）
• WuXi Biologics（China）
• WuXi AppTec（China）
• Boehringer Ingelheim（Germany）
• WuXi Biologics（China）
• WuXi AppTec（China）
• Boehringer Ingelheim（Germany）
• WuXi Biologics（China）
• WuXi AppTec（China）
• Boehringer Ingelheim（Germany）

结论和建议

mRNA Therapeutics Market size was valued at USD 11.0 billion in 2023 and is poised to grow from USD 11.71 billion in 2024 to USD 19.39 billion by 2032, growing at a CAGR of 6.5% during the forecast period (2025-2032).

The mRNA therapeutics market has experienced significant growth, particularly in treating chronic conditions, driven by the successful deployment of mRNA vaccines during the COVID-19 pandemic, primarily by Moderna and Pfizer-BioNTech. These vaccines are increasingly preferred over DNA alternatives due to their safety and efficiency in production and distribution. Their success in human clinical trials has heightened demand, particularly in oncology, where cancer mRNA vaccine trials garnered substantial volunteer interest. As new SARS-CoV-2 variants emerge, the need for effective mRNA solutions becomes more urgent. Advancements in technology are enhancing mRNA product stability and delivery, suggesting a promising future for this sector, which is set to transform personalized medicine and reshape healthcare standards, further fueling market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Mrna Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Mrna Therapeutics Market Segments Analysis

Global mRNA Therapeutics Market is segmented by Type, Application, End-user and region. Based on Type, the market is segmented into Prophylactic and Therapeutic. Based on Application, the market is segmented into Infectious Diseases, Oncology, Rare Genetic Diseases,respiratory diseasesand Others. Based on End-user, the market is segmented into Hospitals & Clinics, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Mrna Therapeutics Market

The rapid advancement of mRNA vaccine technology during the COVID-19 pandemic has significantly propelled the mRNA therapeutics market. This health crisis highlighted mRNA's efficacy as a robust mechanism for addressing infectious diseases, paving the way for its broader application in therapeutics. As a result, mRNA has emerged not only as a crucial defense against viruses but also as a promising platform for developing treatments for various diseases, including cancer and genetic disorders. The momentum gained from pandemic-related research and development is expected to continue driving innovation and investment in the mRNA therapeutics sector, solidifying its position in modern medicine.

Restraints in the Mrna Therapeutics Market

The global mRNA therapeutics market faces several constraints, particularly regarding its production and distribution processes. One significant challenge is the need to scale up mRNA production capacity while ensuring a reliable supply chain. This has been particularly problematic during instances like a global health pandemic, which exacerbates the difficulties of maintaining consistent production levels and distribution efficiency. The complexities of establishing and optimizing these processes hinder market growth and innovation, underscoring the need for improved infrastructure and strategic planning within the mRNA therapeutics landscape to effectively meet increasing demand and overcome logistical challenges.

Market Trends of the Mrna Therapeutics Market

The mRNA therapeutics market is witnessing a significant upward trend, particularly in the development of mRNA cancer vaccines, which offer promising advancements in oncology treatment. As research in this field evolves, pharmaceutical companies are increasingly investing in mRNA technology to create tailored vaccines that stimulate the immune system to target specific cancer cells. This innovation not only enhances the potential for personalized medicine but also showcases the adaptability of mRNA platforms beyond infectious diseases, drawing attention from investors and stakeholders alike. Consequently, the mRNA cancer vaccine segment is poised for substantial growth, driving breakthroughs in cancer therapy and ultimately transforming patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global mRNA Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Prophylactic
• Therapeutic

Global mRNA Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Respiratory Diseases
• Others

Global mRNA Therapeutics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Research Organizations
• Others

Global mRNA Therapeutics Market Size & CAGR (2025-2032)

• North America (Type, Application, End-user)
  • US
  • Canada
• Europe (Type, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CordenPharma (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations